Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Long Term Follow up of BMT CTN 1301 Progress II Trial

The BMT CTN 1301 trial evaluated the role of calcineurin Inhibitor (CNI)-free approaches using T-cell depletion, either by ex vivo CD 34 selection or in vivo post-transplant cyclophosphamide (PTCy) without additional immune suppression compared to tacrolimus and methotrexate with bone marrow grafts and MAC. It demonstrated no difference in the primary composite endpoint of chronic GVHD, relapse-free survival (CRFS) and worse overall survival (OS) with CD-34 selection, despite low rates of chronic GVHD.

https://www.astctjournal.org/article/S2666-6367(23)01818-3/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Marcelo C. Pasquini, Robert Soiffer, Brent Logan, Manmeet Kaur, Steven M. Devine, Nancy Geller, Sergio A. Giralt, Helen E. Heslop, Mary M. Horowitz, Mark R. Litzow, Adam Mendizabal, Lori S Muffly, Eneida Nemecek, Lynn C. O'Donnell, Johannes Schetelig, Ley Tags: 56 Source Type: research